Endo International | ENDP - Umsatzkosten



Umsatzkosten Veränderung Datum
AbbVie USD 4.55B 757M 2025-12
Amarin USD 16.89M 18.51M 2025-03
ANI Pharmaceuticals USD 122.88M 6.86M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Coherus Biosciences USD 2.65M 31.2M 2025-03
Eli Lilly USD 3.37B 363.7M 2025-12
Heron Therapeutics USD 9.46M 1.61M 2024-09
Hikma Pharmaceutical USD 959M 492.5M 2025-12
Ligand Pharmaceuticals USD 11.9M 733K 2025-09
Merck USD 3.32B 531M 2025-12
Novartis USD 3.54B 217M 2025-09
Pacira USD 54.62M 6.02M 2025-12
Perrigo USD 747.4M 81.2M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Phibro Animal Health USD 207.39M 30.45M 2024-12
Supernus Pharmaceuticals USD 47.53M 4.24M 2025-12
Takeda JPY 401.15B 184.07B 2025-12
Teva Pharmaceutical Industries USD 2.06B 120M 2025-12
Xeris Pharmaceuticals USD 13.71M 1.81M 2025-09
Zoetis USD 743M 60M 2025-12